Reversal of acute renal impairment by bortezomib-doxorubicin-dexamathasone in multiple myeloma. Results from an phase II study

LUDWIG, H., Zdeněk ADAM, R. GREIL, E. TÓTHOVÁ, F. KEIL, N. ZOJER, J. THALER, H. GISSLINGER, M. EGYED and A. LANG. Reversal of acute renal impairment by bortezomib-doxorubicin-dexamathasone in multiple myeloma. Results from an phase II study. 2009.

Basic information

Original name

Reversal of acute renal impairment by bortezomib-doxorubicin-dexamathasone in multiple myeloma. Results from an phase II study

Authors

LUDWIG, H., Zdeněk ADAM, R. GREIL, E. TÓTHOVÁ, F. KEIL, N. ZOJER, J. THALER, H. GISSLINGER, M. EGYED and A. LANG

Edition

2009

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

Organization unit

Faculty of Medicine

Keywords in English

multiple myeloma; dexamethasone; bortezomib;doxorubicin

Tags

bortezomib, dexamethasone, doxorubicin, multiple myeloma

Tags

International impact